In addition to altered interferon and other inflammatory responses, subjects with early symptomatic COVID-19 exhibited marked upregulation of B-cell activation (CD79A/B) and a broad diversity of immunoglobulin genes (IGHG1, IGHV2-5, IGHV3.30, IGLV3-19, IGLV3-25, and others) compared to other infectious states (Fig. 4). The gene discussed is IGHG1; the disease is COVID-19.